ReNeuron gets good results in artery disease tests

	Tweet

ReNeuron reported on Monday positive results in preclinical trials of its lead line of stem cells for Peripheral arterial disease (PAD).

PAD affects at least one in 20 people over the age of 55 and is commonly associated with other conditions such as diabetes, obesity and stroke.

In rodent tests the cells were seen to generate “significant” recovery of blood flow in an affected limb, ReNeuron said.

"This work will ... give us a significant advantage as we look to move this cell line forward to the clinic as a non patient-specific therapeutic candidate for Peripheral arterial disease,” said Chief Scientific Officer John Sinden in a statement.

PAD and retinal diseases are key targets for the company alongside strokes for which the company got UK approval to start human trials in January.

Stem cells operate as “master cells” in the body that scientists hope to coax into repairing damaged tissue, but getting regulators to approve tests on humans has proved difficult because the technology is so new.

LONDON (Reuters)

RELATED STORIES:
Fat Outside of Arteries May Influence Onset of Coronary Artery Disease   Hard Arteries More Likely with Diabetes   Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines   Losing belly fat, whether from a low-carb or a low-fat diet, helps improve blood vessel function   Stenting for stroke prevention becoming safer in high-risk patients   Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows   Exercise may be better than stents for PAD patients   Protein causes varicose veins   Use of sulodexide in patients with peripheral vascular disease   Scientists discover the proteins that control development of varicose veins   International Consortium Identifies 5 New Genes Affecting The Risk Of Coronary Artery Disease   Study shows soy protein reduced progression of clogged arteries in women within 5 years of menopause

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]